YOLFTbeta
Tempest Therapeutics Inc

Tempest Therapeutics Inc

TPST · NASDAQ · Healthcare / Biotechnology

0.3819USD-0.00 (-0.29%)

Price History

Full chart

Market Stats

Previous Close0.383
Open0.383
Day Range0.3641 – 0.3898
52-Week Range0.743 – 12.23
Volume152.92K
Market Cap13.71M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.68
Dividend Yield0.00%
Beta-1.66
50-Day Avg0.9796
200-Day Avg1.80

About

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Matthew Angel Ph.D.
  • Employees4
  • Headquarters2000 Sierra Point Parkway, Brisbane, CA, United States, 94005, USA
  • Websitehttps://www.tempesttx.com

Leadership

  • Dr. Matthew Angel Ph.D.President, CEO & Director · b. 1981
  • Mr. Nicholas J. Rossettos CPA, M.B.A.CFO, Principal Financial & Accounting Officer, Treasurer and Corporate Secretary · b. 1966
  • Dr. Andrew Fang Ph.D.Head of Business Development

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---9.73M277.00K653.00K295.00K--000000
Growth (%)-----97.15%+135.74%-54.82%--------
Cost of Revenue-93.00K231.00K450.00K2.25M5.40M28.00K32.00K1.05M815.00K1.27M1.81M381.00K389.00K-
Gross Profit---9.73M-1.97M-4.75M267.00K-32.00K-1.05M-815.00K-1.27M-1.81M-381.00K-389.00K-
Gross Margin---100.00%-711.91%-727.11%90.51%--------
Operating Expense---57.67M70.03M76.26M20.75M23.08M44.35M18.48M25.72M32.83M28.78M41.64M-
Operating Income-2.62M-13.53M-29.13M-47.93M-72.00M-81.01M-20.48M-23.12M-45.40M-19.30M-26.99M-34.64M-29.16M-42.03M-26.57M
Operating Margin----492.38%-25992.42%-12406.13%-6943.05%--------
EBITDA-2.62M-13.44M-28.81M-49.07M-71.86M-79.82M-84.27M-27.01M-43.52M-18.39M-26.65M-33.45M-27.66M-40.14M-25.79M
EBITDA Margin----504.06%-25941.52%-12223.74%-28566.10%--------
Net Income-2.73M-13.51M-29.04M-49.52M-73.22M-82.26M-84.58M-27.19M-44.57M-19.12M-28.30M-35.71M-29.49M-41.84M-26.26M
Net Income Margin----508.68%-26432.85%-12597.24%-28670.51%--------
R&D1.17M6.32M15.80M21.78M18.43M21.64M14.53M14.43M27.84M14.39M17.17M22.53M17.50M28.48M12.61M
R&D as % of Total Revenue---223.77%6654.51%3314.09%4924.07%--------
Interest Expense-000436.00K659.00K0134.00K1.04M507.00K1.28M1.62M1.45M1.32M207.00K
Interest Expense % of Total Revenue---0.00%157.40%100.92%0.00%--------

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.58M32.81M47.55M65.57M138.61M122.54M19.81M84.07M74.97M22.86M73.24M46.09M51.60M41.49M16.93M
Total Liabilities762.00K2.09M5.84M10.25M11.76M14.32M4.83M10.95M15.10M91.66M37.12M27.98M24.84M22.36M10.26M
Total Equity3.82M30.72M41.70M55.33M126.85M108.22M2.23M70.95M58.55M-68.79M36.12M18.11M26.77M19.13M6.67M
Cash4.54M14.78M18.08M6.41M43.42M43.93M15.70M73.33M63.51M18.82M51.83M31.23M39.23M30.27M7.71M
Total Debt------773.00K572.00K4.52M2.44M18.54M22.11M20.66M15.37M8.14M
Net Debt-4.54M-14.78M-18.08M-6.41M-43.42M-43.93M-16.85M-72.76M-58.99M-16.38M-33.29M-9.12M-18.57M-14.90M434.00K

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.16M-18.09M-30.59M-50.29M-61.73M-20.34M-23.65M-41.22M-19.02M-25.96M-31.07M-27.36M-33.03M-26.82M
Investing Cash Flow-17.64M-11.02M-32.79M-38.29M8.29M458.00K1.12M3.99M-6.00K-97.00K-562.00K-170.00K-435.00K-
Financing Cash Flow39.03M32.41M51.71M125.39M54.15M-4.46M78.55M26.94M34.60M59.06M11.40M35.60M24.50M4.26M
Capital Expenditure849.00K719.00K2.80M5.23M2.59M4.00K36.00K397.00K50.00K135.00K562.00K170.00K435.00K0
Free Cash Flow-12.01M-18.81M-33.39M-55.52M-64.32M-20.34M-23.68M-41.62M-19.07M-26.09M-31.63M-27.53M-33.46M-26.82M
FCF to OCF107.61%103.97%109.17%110.40%104.19%100.02%100.15%100.96%100.26%100.52%101.81%100.62%101.32%100.00%

Earnings

Report DateNov 28, 2012Feb 25, 2013May 15, 2013Aug 13, 2013Nov 13, 2013Feb 27, 2014May 8, 2014Aug 7, 2014Nov 10, 2014Mar 16, 2015May 11, 2015Aug 10, 2015Nov 5, 2015Feb 25, 2016May 5, 2016Aug 4, 2016Nov 3, 2016Mar 2, 2017May 9, 2017Aug 3, 2017Nov 2, 2017Mar 15, 2018May 3, 2018Aug 9, 2018Nov 9, 2018Mar 29, 2019May 15, 2019Aug 12, 2019Nov 13, 2019Mar 11, 2020May 8, 2020Aug 10, 2020Nov 9, 2020Mar 29, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 29, 2022May 13, 2022Aug 15, 2022Nov 8, 2022Mar 22, 2023May 10, 2023Aug 10, 2023Nov 8, 2023Mar 19, 2024May 9, 2024Aug 8, 2024Nov 12, 2024Mar 17, 2025May 13, 2025Aug 11, 2025Nov 5, 2025Mar 30, 2026May 15, 2026Aug 13, 2026Nov 4, 2026
EPS Estimate--65.25-61.87-61.87-77.62-88.50-104.25-101.62-101.25-131.79-158.55-144.64-149.79-158.59-162.00-176.40-138.37-129.94-95.96-94.33-89.78-61.95-0.28-0.27-4.05-12.85-10.55-12.12-12.38-12.18-10.00-8.20-6.90-5.15-5.25-11.37-13.61-16.03-1.12-12.00-9.88-0.76-8.54-7.54-7.19-0.39-4.94-5.33-4.58-0.24-3.29-3.23-3.27-0.62-0.28-0.30-0.32
EPS Actual-1226.16-74.25-87.75-81.00-90.00-81.00-92.25-94.50-121.50-177.75-146.25-144.00-148.50-171.00-180.00-139.50-121.50-110.25-85.50-114.75-58.50-54.00-3.15-3.30-0.79-12.30-11.70-11.10-13.05-13.05-9.75-8.40-5.10-5.85-6.60-13.69-15.73-7.93-1.18-10.27-8.58-0.63-7.15-7.02-6.24-0.38-4.68-5.46-5.33-0.31-3.16-2.07-0.79-0.62-0.50-0.34-
Surprise--13.79%-41.83%-30.92%-15.95%8.47%11.51%7.01%-20.00%-34.87%7.76%0.44%0.86%-7.83%-11.11%20.92%12.19%15.15%10.90%-21.65%34.84%12.83%-1025.00%-1122.22%80.49%4.28%-10.90%8.42%-5.41%-7.14%2.50%-2.44%26.09%-13.59%-25.71%-20.40%-15.58%50.53%-5.36%14.42%13.16%17.11%16.28%6.90%13.21%2.56%5.26%-2.44%-16.38%-26.53%3.95%35.91%75.84%0.00%-79.96%-13.33%-
Timing--------Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-market-After-hours-

Key Statistics & Ratios

Market Cap13.71M
Enterprise Value21.95M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book22.94
EPS-3.68
Book Value0.057
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-21.41M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-931.14%
Return on Assets-79.37%
Shares Outstanding16.54M
Shares Float11.07M
Beta-1.66
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 2 analystsTarget 7.00
  • Hold
    2

Ownership Breakdown

Institutions
29.57%
Insiders
31.78%
Retail / Other
38.65%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    233.89K1.41%
  • Geode Capital Management, LLC
    86.99K0.53%
  • Vanguard Fiduciary Trust Co
    68.91K0.42%
  • BlackRock Inc
    39.07K0.24%
  • FMR Inc
    33.23K0.20%
  • Citadel Advisors Llc
    19.82K0.12%
  • Sabby Management LLC
    17.86K0.11%
  • Northern Trust Corp
    14.05K0.09%
  • UBS Group AG
    4.53K0.03%
  • Tower Research Capital LLC
    2.79K0.02%
  • Morgan Stanley - Brokerage Accounts
    2.06K0.01%
  • Advisor Group Holdings, Inc.
    1.53K0.01%
  • Federation des caisses Desjardins du Quebec
    2920.00%
  • JONES FINANCIAL COMPANIES LLLP
    2390.00%
  • Vanguard Global Advisers, LLC
    1680.00%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    104.94K0.63%
  • Fidelity Extended Market Index
    48.45K0.29%
  • Abante Quant Value FI
    41.82K0.25%
  • Fidelity Series Total Market Index
    15.68K0.09%
  • Fidelity Total Market Index
    7.50K0.05%

Stock Splits

  • Apr 9, 20251:13
  • Jun 28, 20211:15
  • Dec 10, 20181:15